3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Thyroid Neoplasms
1
Pancreatic Neoplasms
1
Melanoma
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
23
Nivolumab
10
Trastuzumab
7
Gemcitabine
6
Cisplatin
6
Cetuximab
6
Docetaxel
5
spartalizumab
4
atezolizumab
4
Ipilimumab
4
Drug Therapy
4
Cyclophosphamide
4
Carboplatin
4
Capecitabine
4
palbociclib
3
fludarabine
3
cemiplimab
3
Radiotherapy
3
Magnetic Resonance Spectroscopy
3
Erlotinib Hydrochloride
3
Bortezomib
3
ulixertinib
2
trametinib
2
sargramostim
2
pertuzumab
2
avelumab
2
amminedichloro(2-methylpyridine)platinum(II)
2
aldesleukin
2
Taxes
2
TH 302
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
naporafenib
×
Head & Neck
×
Clear all
NCT05907304
2026-02-27
SEACRAFT-1
Erasca, Inc.
Phase 1
Active not recruiting
86 enrolled